Morgan Stanley Greenwich Life Sciences, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 13,774 shares of GLSI stock, worth $169,420. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,774
Previous 17,031
19.12%
Holding current value
$169,420
Previous $244,000
36.89%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding GLSI
# of Institutions
39Shares Held
1.11MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY309KShares$3.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA275KShares$3.38 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA134KShares$1.65 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL87.4KShares$1.08 Million0.0% of portfolio
-
Credit Agricole S A87KShares$1.07 Million0.0% of portfolio
About Greenwich LifeSciences, Inc.
- Ticker GLSI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,848,200
- Market Cap $158M
- Description
- Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...